FitLife Brands (FTLF)
NASDAQ:FTLF
Top Page
FitLife Brands
(NASDAQ:FTLF)
Select Model
Select Model
Rating:62Neutral
Price Target:
$11.00
▼(-22.70% Downside)
Action:ReiteratedDate:04/03/26
The score reflects solid-but-not-clean fundamentals (strong growth and improving leverage, but meaningful margin and cash-flow deterioration) as the primary driver. Technicals are notably weak with the stock in a clear downtrend, while valuation offers only moderate support at a ~24 P/E. Earnings-call takeaway is mixed: acquisition-driven growth and debt paydown are positives, but no formal 2026 guidance and ongoing operational/margin issues limit upside conviction.
Positive Factors
Balance-sheet improvement
Declining leverage and a stronger equity base materially increase financial flexibility over the next 2–6 months. Lower debt burden reduces interest risk, supports continued term‑loan paydowns, and gives management runway to invest in supply‑chain fixes, NPD and cross‑sell without immediate refinancing pressure.
Negative Factors
Margin compression
Material margin deterioration reflects lower‑margin wholesale mix from Irwin, inventory/amortization costs and input‑cost pressure. Sustained margin compression reduces cash generation and returns, raising execution risk: restoring prior margin levels will require successful supply‑chain fixes and product/mix improvements over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet improvement
Declining leverage and a stronger equity base materially increase financial flexibility over the next 2–6 months. Lower debt burden reduces interest risk, supports continued term‑loan paydowns, and gives management runway to invest in supply‑chain fixes, NPD and cross‑sell without immediate refinancing pressure.
Read all positive factors
FitLife Brands (FTLF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$92.03M
Dividend YieldN/A
Average Volume (3M)13.44K
Price to Earnings (P/E)23.2
Beta (1Y)0.66
Revenue Growth12.44%
EPS Growth-20.33%
CountryUS
Employees39
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.16
Shares Outstanding9,391,072
10 Day Avg. Volume14,597
30 Day Avg. Volume13,441
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)3.48
Price to Sales (P/S)1.87
P/FCF Ratio20.56
Enterprise Value/Market Cap1.47
Enterprise Value/Revenue1.67
Enterprise Value/Gross Profit4.31
Enterprise Value/Ebitda12.90
Forecast
1Y Price Target
$17.50Price Target Upside22.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.24
Revenue Forecast (FY)$102.00M
FitLife Brands Business Overview & Revenue Model
Company Description
FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. It offers weight loss, general health, and sports nutrition supplements; precision sports nutrition formulations for pro...
How the Company Makes Money
FitLife Brands makes money primarily by selling nutritional supplements and related wellness products under its brand portfolio. Its core revenue stream is product sales, with a significant portion generated through direct-to-consumer channels (co...
FitLife Brands Earnings Call Summary
Earnings Call Date:Apr 01, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 20, 2026
Earnings Call Sentiment Neutral
The call was mixed: several material positives (Irwin acquisition and rapid online scaling, substantial Q4 revenue lift, contribution and adjusted EBITDA growth, and disciplined debt paydown) are tempered by clear ongoing weaknesses (legacy brand declines, MRC underperformance, margin compression from Irwin, inventory obsolescence, Amazon traffic headwinds, and protein input-cost pressures). Management outlined credible operational fixes (shelf-life extension, supply-chain hires, off-Amazon marketing, new product launches and cross-selling) but timing and magnitude of recovery remain uncertain, and management withheld 2026 guidance as a result.Positive Updates
Irwin Acquisition and Early Scaling
Acquired Irwin Naturals on August 8, 2025; Irwin Q4 revenue $12.6M (89% wholesale), delivered ~6% organic growth in Q4 vs. 2024 when normalized for lost Costco/Rite Aid/CBD; Amazon ramp: Oct $60k, Nov $300k, Dec ~ $500k; online monthly run-rate grew from ~$0.5M at end of Q4 to ~$0.8M in Q1 2026 (implying $9M–$10M annualized); subscribers increased from ~500 to over 3,600.
Negative Updates
Legacy FitLife Q4 Revenue and Contribution Decline
Legacy FitLife Q4 revenue was $13.3M and fell 12% year-over-year (wholesale down 14%, online down 10%); contribution declined 18% to $4.3M and contribution margin fell to 32.5% from 34.9%.
Read all updates
Q4-2025 Updates
Positive
Negative
Irwin Acquisition and Early Scaling
Acquired Irwin Naturals on August 8, 2025; Irwin Q4 revenue $12.6M (89% wholesale), delivered ~6% organic growth in Q4 vs. 2024 when normalized for lost Costco/Rite Aid/CBD; Amazon ramp: Oct $60k, Nov $300k, Dec ~ $500k; online monthly run-rate grew from ~$0.5M at end of Q4 to ~$0.8M in Q1 2026 (implying $9M–$10M annualized); subscribers increased from ~500 to over 3,600.
Read all positive updates
Company Guidance
Management declined to give formal 2026 guidance because of first‑quarter weakness and uncertainty, but provided metric context: consolidated Q4 2025 revenue was $25.9M (+73% YoY) with wholesale $15.5M (60% of revenue, +213%) and online $10.5M (40%, +4%); adjusted gross margin excluding the Irwin inventory step‑up amortization was 37.0% (vs. 41.4% prior), contribution rose 47%, net income was $1.6M (vs. $2.1M) and adjusted EBITDA was $3.5M (+14%). For 2025, legacy FitLife (ex‑MRC/MusclePharm) grew organic revenue ~6% with online +16% and wholesale flat, MusclePharm grew ~5% while MRC declined ~15%; legacy FitLife Q4 revenue was $13.3M (68% online, 32% wholesale) and contribution fell 18% to $4.3M (32.5% of revenue). Irwin (acquired Aug 8, 2025) normalized revenue was $54M in both 2024 and 2025, Q4 Irwin revenue was $12.6M (89% wholesale), Q4 gross margin 28.0% (33.2% adjusted) and contribution 26.6% (31.8% adjusted); Irwin Amazon sales scaled from ~$60k (Oct) to ~$300k (Nov) to ~$500k (Dec) and are running ≈$0.8M/month in Q1 2026 (≈$9–10M annual run‑rate) with subscribers rising from ~500 to >3,600. Balance‑sheet actions include ~$1.9M term‑loan paydown in Q4 to a $44.7M balance, a ~$1.4M revolver reduction in Q1 and an additional ~$1.5M term payment, and management highlighted five priorities (supply‑chain fixes to eliminate ~$2M/year of obsolescence and potentially lift Irwin margins 300–400 bps, NPD, off‑Amazon demand generation, wholesale cross‑selling, and SG&A efficiency) before issuing formal guidance.FitLife Brands Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
66
Positive
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 81.46M | 64.47M | 52.70M | 28.80M | 27.91M |
| Gross Profit | 31.45M | 28.08M | 21.43M | 12.03M | 12.50M |
| EBITDA | 10.51M | 13.35M | 8.12M | 5.89M | 6.29M |
| Net Income | 6.33M | 8.98M | 5.30M | 4.43M | 5.41M |
Balance Sheet | |||||
| Total Assets | 106.32M | 58.53M | 55.35M | 25.71M | 21.51M |
| Cash, Cash Equivalents and Short-Term Investments | 1.65M | 4.47M | 1.14M | 13.28M | 9.90M |
| Total Debt | 45.25M | 13.46M | 20.15M | 103.00K | 158.00K |
| Total Liabilities | 62.68M | 22.41M | 28.31M | 4.32M | 4.16M |
| Stockholders Equity | 43.64M | 36.13M | 27.04M | 21.39M | 17.35M |
Cash Flow | |||||
| Free Cash Flow | 7.40M | 9.60M | 4.11M | 4.13M | 4.48M |
| Operating Cash Flow | 7.44M | 9.61M | 4.22M | 4.13M | 4.48M |
| Investing Cash Flow | -42.54M | -10.00K | -35.99M | 0.00 | -529.00K |
| Financing Cash Flow | 32.09M | -6.98M | 20.30M | -750.00K | -390.00K |
FitLife Brands Technical Analysis
Negative
14.23
Price Trends
14.36
Negative
15.70
Negative
16.26
Negative
Market Momentum
-0.98
Positive
22.36
Positive
6.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FTLF, the sentiment is Negative. The current price of 14.23 is above the 20-day moving average (MA) of 13.13, below the 50-day MA of 14.36, and below the 200-day MA of 16.26, indicating a bearish trend. The MACD of -0.98 indicates Positive momentum. The RSI at 22.36 is Positive, neither overbought nor oversold. The STOCH value of 6.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FTLF.
FitLife Brands Risk Analysis
FitLife Brands disclosed 13 risk factors in its most recent earnings report. FitLife Brands reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
FitLife Brands Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.44B | 5.80 | -36.19% | ― | -0.78% | 265.56% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
62 Neutral | $92.03M | 23.18 | 16.34% | ― | 12.44% | -20.33% | |
61 Neutral | $434.89M | 19.90 | 12.18% | ― | 6.62% | -7.85% | |
56 Neutral | $51.69M | 70.54 | 24.97% | 2.81% | 16.77% | 143.30% | |
53 Neutral | $323.73M | 33.56 | 2.03% | ― | 5.88% | -68.62% | |
45 Neutral | $70.06M | -0.21 | -111.73% | ― | -10.13% | -532.32% |
* Consumer Defensive Sector Average
FTLF
FitLife Brands
9.80
-1.15
-10.50%
HLF
Herbalife
13.94
6.88
97.45%
NATR
Nature's Sunshine Products
24.84
12.83
106.83%
HAIN
Hain Celestial
0.77
-2.64
-77.42%
USNA
USANA Health
17.54
-6.67
-27.55%
LFVN
LifeVantage
4.04
-9.50
-70.16%
FitLife Brands Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
FitLife Brands Q4 2025 Results Highlight Irwin Acquisition
Neutral
Apr 1, 2026
FitLife Brands reported its fourth-quarter and full-year 2025 results on April 1, 2026, showing that the August 8 acquisition of Irwin Naturals drove a 73% year-on-year jump in quarterly revenue to $25.9 million and a 26% rise in annual revenue to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.